leadf
logo-loader
viewMydecine Innovations Group Inc
(
OTC:MYCOFFRA:0NFANEO:MYCO
)

Mydecine launching Mindleap 2.0, an online community for psychedelic education and support

The platform features a media library with guided meditations, educational content and an online community connecting users to mental health specialists

The Parent Company -
Mindleap is also being designed to support patient care and monitoring for the parent company’s clinical trials

Mydecine Innovations Group (NEO:MYCO) (OTCMKTS:MYOCF) (FRA:0NFA) announced its subsidiary Mindleap Health is debuting a new version of its virtual health platform at the end of the month. 

The virtual “2.0” version of Mindleap is an online platform that supports the integration of psychedelics to support personal wellness and mental health. 

According to Mydecine, the platform features a media library with guided meditations, educational content and an online community connecting users to mental health specialists. 

READ: Mydecine selects substance use disorder and smoking cessation for its psychedelic molecule MYCO-004

Users can attend encrypted video support sessions through the platform and receive advice from health and wellness specialists, who work with psychedelics.

The content on Mindleap is developed in conjunction with researchers and practitioners from the field of mental health, neuroscience and psychedelics, from institutions such as Imperial College of London, Yale, and MAPS.

“The platform provides the optimal community space for users to develop trust in and connect with support professionals,” said Nicholas Martin, Mindleap’s director of specialists and community, said in a statement. “Users will be able to connect with integration specialists, who have demonstrated experience and training from psychedelic integration training programs.”

Mydecine said that Mindleap is also being designed to support patient care and monitoring for the parent company’s clinical trials.

Denver-based Mydecine’s development pipeline includes its flagship product MYCO-001, which is a purified form of psilocybin, that is being tested as a novel therapy for post-traumatic stress disorder (PTSD). 

Contact Angela at angela@proactiveinvestors.com

Follow her on Twitter @AHarmantas

Quick facts: Mydecine Innovations Group Inc

Follow
OTC:MYCOF

Price: 0.2758 USD

Market Cap: $65.83 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Mydecine Innovations Group outlines plan for MYCO-001 Phase 2/3 Smoking...

Mydecine Innovations Group Inc (OTC:MYCOF, FRA:0NFA, NEO:MYCO) (OTCMKTS:MYCOF) (FRA:0NFA) (NEO:MYCO) CEO Joshua Bartch tells Proactive it has partnered with Principal Investigator Dr Matthew Johnson of Johns Hopkins University on a study evaluating the administration of its lead drug candidate...

1 week, 4 days ago

2 min read